COMPANY PROFILE

Poxel

Explore full profile

Research integrated pharmaceutical company that develops products for metabolic diseases

Lyon, FranceFounded 2009Biotech & Life Sciences

Valuation $28M Market cap · 2026

Revenue $5.5M Latest reported FY

Total funding $50–100M Disclosed equity funding

About Poxel

Poxel SA is a French biopharmaceutical company established in 2009 as a spin-off from Merck Serono. The company was founded by a team of four individuals, including the current CEO, Thomas Kuhn. Mr. Kuhn, who holds a pharmacy degree and an MBA, brought to Poxel his experience from Merck KGaA, where he was involved in the clinical development of treatments for Type 2 diabetes.

Read full description

Poxel focuses on the development of treatments for serious chronic metabolic diseases. The company's primary market includes metabolic disorders such as non-alcoholic steatohepatitis (NASH) and Type 2 diabetes. Its business model is centered on the research and development of novel drug candidates, progressing them through clinical trials, and then partnering with larger pharmaceutical companies for commercialization.

The company's lead product is TWYMEEG® (Imeglimin), an oral drug for the treatment of Type 2 diabetes. Poxel has a strategic partnership with Sumitomo Pharma to commercialize TWYMEEG® in several Asian countries, including Japan, China, and South Korea.

Source: Dealroom company data